Research and Markets: Get the Latest Data on Eli Lilly's R&D Pipeline Products

Dublin — Research and Markets (http://www.researchandmarkets.com/reports/c22260) has announced the addition of Eli Lilly Cancer Company Intelligence Report to their offering

Founded in 1876, Eli Lilly is a research-based company engaged in the discovery, development, manufacture and sale of products and the provision of services in one industry segment, namely Life Sciences, which operates two divisions: Pharmaceuticals and Elanco Animal Health. Its products primarily comprise human and veterinary pharmaceuticals and agricultural products.

Information provided in this profile includes:

- Summary: At a glance review of agreements, products and R&D pipeline.

- Overview: Background, ownership structure and research techniques they have developed for drug discovery.

- Agreements: Key details of who the company is collaborating with, and on what.

- Product Portfolio: Product monographs, mechanism of action and indications approved and in development.

- R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.

- Financials: An analysis of financial performance including P&L, R&D expenditure and funding.

For more information visit http://www.researchandmarkets.com/reports/c22260

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980